Zhi Xiao

987 total citations
37 papers, 600 citations indexed

About

Zhi Xiao is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Zhi Xiao has authored 37 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Molecular Biology and 13 papers in Cancer Research. Recurrent topics in Zhi Xiao's work include Inflammatory Biomarkers in Disease Prognosis (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Risks and Factors (4 papers). Zhi Xiao is often cited by papers focused on Inflammatory Biomarkers in Disease Prognosis (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Risks and Factors (4 papers). Zhi Xiao collaborates with scholars based in China, Germany and Nepal. Zhi Xiao's co-authors include Nianhua Ding, Shouman Wang, Markus W. Büchler, Peter Schemmer, Lili Tang, Katrin Hoffmann, Limin Peng, Xinwu Guo, Lizhong Dai and Jiaqi Yuan and has published in prestigious journals such as PLoS ONE, Cancer Research and Scientific Reports.

In The Last Decade

Zhi Xiao

37 papers receiving 597 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhi Xiao China 16 282 242 194 85 65 37 600
Xianqiu Wu China 15 483 1.7× 193 0.8× 223 1.1× 115 1.4× 42 0.6× 26 740
Zehua Wang China 13 275 1.0× 185 0.8× 187 1.0× 103 1.2× 60 0.9× 32 562
Zhi Dai China 11 347 1.2× 246 1.0× 214 1.1× 73 0.9× 44 0.7× 16 744
Yibin Ren China 12 365 1.3× 149 0.6× 163 0.8× 46 0.5× 53 0.8× 13 531
Xuefeng Hua China 9 195 0.7× 317 1.3× 148 0.8× 43 0.5× 50 0.8× 21 691
Andrea Pretta Italy 12 182 0.6× 272 1.1× 139 0.7× 102 1.2× 61 0.9× 47 478
Timothy Wai Ho Shuen Singapore 12 350 1.2× 135 0.6× 201 1.0× 83 1.0× 46 0.7× 22 563
Guohe Song China 10 216 0.8× 131 0.5× 142 0.7× 91 1.1× 51 0.8× 19 471
Zhiming Wang China 15 402 1.4× 154 0.6× 320 1.6× 80 0.9× 41 0.6× 32 638
Guang-Ang Tian China 13 324 1.1× 166 0.7× 180 0.9× 93 1.1× 41 0.6× 20 582

Countries citing papers authored by Zhi Xiao

Since Specialization
Citations

This map shows the geographic impact of Zhi Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhi Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhi Xiao more than expected).

Fields of papers citing papers by Zhi Xiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhi Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhi Xiao. The network helps show where Zhi Xiao may publish in the future.

Co-authorship network of co-authors of Zhi Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Zhi Xiao. A scholar is included among the top collaborators of Zhi Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhi Xiao. Zhi Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qi, Robert Z., Xianzhong Chen, Zihan Li, et al.. (2024). Tracking Chaperone-Mediated Autophagy Flux with a pH-Resistant Fluorescent Reporter. International Journal of Molecular Sciences. 26(1). 17–17. 1 indexed citations
2.
Pang, Jian, et al.. (2024). Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy. Scientific Reports. 14(1). 6578–6578. 10 indexed citations
3.
Ding, Nianhua, Jian Pang, Xuan Liu, et al.. (2024). Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial. Breast Cancer Research. 26(1). 9–9. 3 indexed citations
5.
Pang, Jian, Haiyan Zhou, Xue Dong, Shouman Wang, & Zhi Xiao. (2021). Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer. Clinical Breast Cancer. 21(6). e681–e687. 13 indexed citations
6.
Hu, Huiyu, Nianhua Ding, Haiyan Zhou, et al.. (2021). A novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report. Journal of Medical Case Reports. 15(1). 277–277. 2 indexed citations
7.
Li, Xuefei, Zhuo Li, Miao Yang, et al.. (2021). Two tSNPs in BRIP1 are associated with breast cancer during TDT analysis. Molecular Genetics & Genomic Medicine. 9(2). e1578–e1578. 2 indexed citations
10.
Yuan, Jiaqi, Nianhua Ding, & Zhi Xiao. (2020). The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients. Frontiers in Pharmacology. 11. 537265–537265. 10 indexed citations
12.
Li, Guoli, Xinwu Guo, Lili Tang, et al.. (2017). Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing. Journal of Cancer Research and Clinical Oncology. 143(10). 2011–2024. 30 indexed citations
13.
Li, Zibo, Jianfu Heng, Xinwu Guo, et al.. (2016). Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients. Breast Cancer Research and Treatment. 160(2). 371–383. 30 indexed citations
14.
Li, Zibo, Xinwu Guo, Shengyun Li, et al.. (2015). Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients. Breast Cancer Research and Treatment. 149(3). 767–779. 49 indexed citations
15.
Yuan, Jiaqi, Jie Mao, Yuhui Wu, et al.. (2015). Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 151(2). 405–413. 22 indexed citations
16.
Lin, Shibo, Katrin Hoffmann, Zhi Xiao, et al.. (2013). MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. Cancer Cell International. 13(1). 3–3. 20 indexed citations
17.
Xiao, Zhi, Nianhua Ding, Guiqing Xiao, et al.. (2012). Reversal of Multidrug Resistance by Gefitinib Via RAF1/ERK Pathway in Pancreatic Cancer Cell Line. The Anatomical Record. 295(12). 2122–2128. 16 indexed citations
18.
Lai, R., Guang‐Jie Zhu, Richard J. Vivero, et al.. (2012). Genetic diagnosis and cochlear implantation for patients with nonsyndromic hearing loss and enlarged vestibular aqueduct. The Journal of Laryngology & Otology. 126(4). 349–355. 19 indexed citations
19.
Hoffmann, Katrin, et al.. (2011). Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. Cancer Cell International. 11(1). 40–40. 20 indexed citations
20.
Hoffmann, Katrin, et al.. (2010). Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.. PubMed. 30(11). 4503–8. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026